![Roberto Galli](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roberto Galli
Financieel Directeur/CFO bij
NEWRON PHARMACEUTICALS S.P.A.
Profiel
Roberto Galli currently works at Newron Sweden AB, as Director, Newron Pharmaceuticals US, Inc., as Secretary, Treasurer & Director, and Newron Pharmaceuticals SpA, as Chief Financial Officer from 2023.
Mr. Galli also formerly worked at PricewaterhouseCoopers SpA, as Senior Auditor from 1996 to 2002 and Coopers & Lybrand SpA, as Auditor.
Mr. Galli received his undergraduate degree from the University of Bocconi.
Actieve functies van Roberto Galli
| Bedrijven | Functie | Begin |
|---|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Financieel Directeur/CFO | 01-01-2012 |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Directeur/Bestuurslid | - |
Newron Pharmaceuticals US, Inc.
 Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Roberto Galli
| Bedrijven | Functie | Einde |
|---|---|---|
PricewaterhouseCoopers SpA
 PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services | Corporate Officer/Principal | 01-10-2002 |
Coopers & Lybrand SpA
 Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company. | Comptroller/Controller/Auditor | - |
Opleiding van Roberto Galli
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
27
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
Newron Sweden AB
Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Bocconi
 University of Bocconi Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PricewaterhouseCoopers SpA
PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services | Commercial Services |
Coopers & Lybrand SpA
Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company. | Commercial Services |
Newron Pharmaceuticals US, Inc.
Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Commercial Services |
Kies MarketScreener 
